$ABBV.TSX Q3 '26 Earnings Results & Recap
AbbVie raised full-year 2026 adjusted diluted EPS guidance from $13.76 - $13.96 to $13.95 - $13.99, including an unfavorable $0.69 per-share impact from acquired IPR&D and milestones expense incurred year-to-date.